In the last a long time, the volume of sufferers referred for allogeneic hematopoietic cell transplantation has dropped appreciably,133 even so the treatment need to be advisable to younger/fit sufferers in whom BCR/BCL2 inhibitor therapy fails, particularly in those with TP53Venetoclax is one of the best alternate options in this situation, includ